Clinical trial for the treatment of infertility via replacement of poor quality ooplasm

Darwin Life, INC0 个研究点目标入组 100 人开始时间: 2019年9月19日最近更新: 2019年10月14日

适应症

试验速览

Zhang, J., et al., Live birth derived from oocyte spindle transfer to prevent mitochondrial disease. Reprod Biomed Online, 2017. 34(4): p. 361-368. 2. Zhang, J., et al., In vitro maturation of human preovulatory oocytes reconstructed by germinal vesicle transfer. Fertil Steril, 1999. 71(4): p. 726-31. 3. Liu, H. et al., In vitro development of human oocytes reconstructed by sequential transfer of germinal vesicle and MII spindle. Fertility and Sterility, Volume 108, Issue 3, e57 - e58 4 Wang X., et al., Novel mutations in genes encoding subcortical maternal complex proteins may cause human embryonic developmental arrest. Reproductive biomedicine online. – 2018. – Vol 36 – N6. – P698-704 5. Narravula A., et al., Three parent baby – Prenatal genetic confirmation of the outcome of mitochondrial replacement therapy. ACMG Annual Meeting – March 2017. – 2017. – AN750. 6. Mazur P., et al., Reverse reconstitution of human zygotes reveals the competence of zygotic cytoplasts in women of advanced maternal age. RBM online. – 2019. – Vol. 38, Supl. 1. – e32-e33. 7. Mykytenko D., et al., Efficacy of nuclear transfer to prevent the inherited mitochondrial pathology. REBM online. – 2019. – Vol 39., Supl. 1. – P. e60.

•Group 1: 41 years old or older, having failed three or more IVF cycles, and still has a regular menstrual cycle. Group 2: 40 years old or younger AND with regular menstrual period AND having failed three or more IVF cycles, OR carrier of Mitochondrial DNA Disease OR a history of failure to form blastocysts.

发起方

Darwin Life, INC